More than 55,000 South Africans have enrolled for the twice‑yearly injectable HIV prevention medication Lenacapavir, marking significant progress in the nationwide rollout launched in June.
According to the Department of Health, the initiative, launched by President Cyril Ramaphosa and Health Minister Aaron Motsoaledi, 55,123 people had been initiated on Lenacapavir by 7 September, with women – particularly pregnant and breastfeeding mothers – making up 71 percent of recipients.
It said the programme has been rolled out to 360 public health facilities across 24 districts in six provinces.
Gauteng leads with more than 26,000 initiations, followed by KwaZulu‑Natal (11,941), North West (4,479), Western Cape (4,446), Mpumalanga (4,294), and Eastern Cape (3,606).
Lenacapavir is being offered as part of a comprehensive HIV prevention programme alongside other pre‑exposure prophylaxis (PrEP) options.
Approved by the South African Health Products Regulatory Authority, the drug has undergone rigorous review of clinical and manufacturing data and is considered safe and effective.
JN/APA



